Background: Respiratory syncytial virus (RSV) is the main cause of bronchiolitis in infants. This systematic review aimed to evaluate the burden of RSV-associated bronchiolitis among hospitalized Italian infants between 2000 and 2023. Methods: A comprehensive literature search identified studies examining RSV-related hospitalizations for bronchiolitis in children aged 0–59 months. Eligible studies met the following criteria: conducted in Italy, focused on children, reported on RSV prevalence, co-infections, genotype distribution (RSV-A, RSV-B), and seasonal trends, and published in English or Italian. Data extraction focused on study design, infant characteristics (e.g., age, preterm birth), and RSV detection methods. Results: Twenty-four studies were included. Infants under 12 months were most affected. RSV was the primary pathogen identified, though co-infections with other respiratory viruses, such as human rhinovirus, were common. RSV infections typically peaked in late autumn and winter, but the COVID-19 pandemic altered these patterns. This review highlights the significant burden of RSV-associated bronchiolitis in Italian infants. While RSV remains the primary pathogen, co-infections and pandemic related factors have altered its epidemiological trends. Conclusions: Nationwide RSV immunization programmes and improved diagnostics are crucial to ease the strain on pediatric intensive care units. Recent recommendations for widespread RSV long-acting monoclonal antibody use in infants offer promising solutions to address this challenge.
Burden and Characteristics of Respiratory Syncytial Virus‐Associated Bronchiolitis in Hospitalized Infants in Italy: A Systematic Review / Bechini, Angela; Salvati, Cristina; Del Riccio, Marco; Bonito, Benedetta; Stancanelli, Enrica; Bruschi, Mario; Ionita, Giulia; Iamarino, Johanna; Bentivegna, Davide; Buscemi, Primo; Ciardi, Giulia; Cosma, Claudia; Stacchini, Lorenzo; Bega, Manjola; Schirripa, Annamaria; Bertizzolo, Lorenzo; Muzii, Barbara; Azzi, Maria Vittoria; Parisi, Salvatore; Trippi, Francesca; Bonanni, Paolo; Boccalini, Sara. - In: IMMUNITY, INFLAMMATION AND DISEASE. - ISSN 2050-4527. - ELETTRONICO. - 14:(2026), pp. e70420.1-e70420.10. [10.1002/iid3.70420]
Burden and Characteristics of Respiratory Syncytial Virus‐Associated Bronchiolitis in Hospitalized Infants in Italy: A Systematic Review
Bechini, Angela;Salvati, Cristina;Del Riccio, Marco
;Bonito, Benedetta;Stancanelli, Enrica;Bruschi, Mario;Ionita, Giulia;Iamarino, Johanna;Bentivegna, Davide;Buscemi, Primo;Ciardi, Giulia;Cosma, Claudia;Stacchini, Lorenzo;Bega, Manjola;Schirripa, Annamaria;Bonanni, Paolo;Boccalini, Sara
2026
Abstract
Background: Respiratory syncytial virus (RSV) is the main cause of bronchiolitis in infants. This systematic review aimed to evaluate the burden of RSV-associated bronchiolitis among hospitalized Italian infants between 2000 and 2023. Methods: A comprehensive literature search identified studies examining RSV-related hospitalizations for bronchiolitis in children aged 0–59 months. Eligible studies met the following criteria: conducted in Italy, focused on children, reported on RSV prevalence, co-infections, genotype distribution (RSV-A, RSV-B), and seasonal trends, and published in English or Italian. Data extraction focused on study design, infant characteristics (e.g., age, preterm birth), and RSV detection methods. Results: Twenty-four studies were included. Infants under 12 months were most affected. RSV was the primary pathogen identified, though co-infections with other respiratory viruses, such as human rhinovirus, were common. RSV infections typically peaked in late autumn and winter, but the COVID-19 pandemic altered these patterns. This review highlights the significant burden of RSV-associated bronchiolitis in Italian infants. While RSV remains the primary pathogen, co-infections and pandemic related factors have altered its epidemiological trends. Conclusions: Nationwide RSV immunization programmes and improved diagnostics are crucial to ease the strain on pediatric intensive care units. Recent recommendations for widespread RSV long-acting monoclonal antibody use in infants offer promising solutions to address this challenge.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



